Table 1.

Efficacy of EBOV vaccines in NHPs

Vaccine	Challenge virus	Vaccine doses	Time to challenge (d)a	Survival (%)	Ref.
Whole virus
inact. EBOV	EBOV	3	43	25	[5]
inact. EBOV	EBOV	2	56	0	[13]
EBOVΔVP30	EBOV	1, 2	28	100	[13]
VLPs
eVLPs + RIBI	EBOV	3	28	100	[6]
VLPs + QS21	EBOV, SUDV, TAFV	1, 2	28	67-100	[69]
DNA
EBOV GP, Filo GPs	EBOV	3	56	83	[31]
DNA + rec. Adenovirus
DNA EBOV GP, EBOV  NP + rAd5-EBOV GP	EBOV	4	90	100	[29]
DNA EBOV GP + rAd5-EBOV GP	BDBV	5	49	100	[70]
Replicon
VEEV-EBOV GP, VEEV-EBOV NP, both	EBOV	3	49	0	[5]
VEEV-SUDV GP + VEEV-EBOV GP	SUDV, EBOV	1	28, 58/63	100	[27]
rec. Adenovirus
rAd5-GP + rAd5-NP	EBOV	1, 2	7, 28	100	[71]
EBOV GP + NP, EBOV GPΔTM + NP	EBOV	1	28	100	[72]
CAdVax-filo GP + NP	EBOV, SUDV	2	42, 114	100	[40]
CAdVax-EBOV M7 + M8	EBOV, SUDV	1, 2	7, 28, 41, 442, 113	100	[73]
rAd26-GP + rAd35-GP	EBOV	2	28	100	[36]
rAd5-GP	EBOV	1	28	100	[34, 74]
Ad-CAGoptZGP + Ad-IFNα	EBOV	1	28	100	[39]
ChAd63-EBOV	EBOV	1	35	100	[41]
ChAd63-EBOV + MVA-BN-filo	EBOV	2	240	100	[41]
Ad-CAGoptZGP	EBOV	1	150	100	[75]
rec. Vaccinia virus
VACV-EBOV GP	EBOV	3	45	0	[5]
rec. Cytomegalovirus
RhCMV/EBOV GP	EBOV	2	28	75	[47]
rec. Human parainfluenza virus
HPIV3-EBOV GP + NP, HPIV3-EBOV GP + GM-CSF	EBOV	1, 2	28	67–100	[52]
HPIV3/EBOV GP	EBOV	1, 2	27	100	[54]
rec. Rabies virus
BNSP(333)-GP, BNSP(333)ΔG/GP, inact. BNSP(333)-GP	EBOV	1, 2	42	100	[48]
inact. BNSP333-coEBOVGP + adjuvants	EBOV	2	28	100	[50]
FILORAB1/GLA-SE	EBOV	2, 3	57, 43	100	[76]
rec. Vesicular stomatitis virus
VSV-EBOV	EBOV	1	28	100	[59, 61, 63, 77, 78]
VSV-EBOV, VSV-SUDV, VSV-MARV	EBOV, SUDV, TAFV	1	28	100	[60]
VSV-EBOV	EBOV	1	7-28	100	[65]
Vesiculovax-rVSV-EBOV GP	EBOV	1	28	100	[58]
Vesiculovax-rVSV-EBOV GP	EBOV	1	28	100	[66]

^aTime until challenge after vaccination was completed